GLP-1 receptor agonists such as semaglutide and tirzepatide are transforming weight and metabolic health. This article explores the benefits, rare pancreatitis risks, MHRA Yellow Card data, genetic research, and how robust clinical governance and monitoring help ensure safe, evidence-based treatment for appropriately selected patients in the UK.